GADOLIN: Combination improves PFS in rituximab-refractory indolent NHL
Posted on: 30/05/2015 - 20:35
CHICAGO – Progression-free survival for patients with rituximab-refractory indolent non-Hodgkin’s lymphoma was effectively doubled with a combination of obinutuzumab and bendamustine, compared with...
Field of Interest: Oncology
Type: News Item